WST vs JNJ

For growth investors, West Pharmaceutical Services, Inc.

(WST) is the stronger pick with 6. 3% revenue growth year-over-year, versus 4. 3% for Johnson & Johnson (JNJ). Johnson & Johnson (JNJ) offers the better valuation at 38. 8x trailing P/E (19. 4x forward), making it the more compelling value choice. Analysts rate West Pharmaceutical Services, Inc. (WST) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Johnson & Johnson (JNJ) is the cheapest at 38.

8x versus West Pharmaceutical Services, Inc. at 46. 0x. On forward P/E, Johnson & Johnson is actually cheaper at 19. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: West Pharmaceutical Services, Inc. wins at 4. 38x versus Johnson & Johnson's 34. 49x.

Over the past 5 years, Johnson & Johnson (JNJ) delivered a total return of +48.

0%, compared to -3. 9% for West Pharmaceutical Services, Inc. (WST). Over 10 years, the gap is even starker: WST returned +353. 8% versus JNJ's +136. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

06β versus West Pharmaceutical Services, Inc. 's 0. 92β — meaning WST is approximately 1509% more volatile than JNJ relative to the S&P 500. On balance sheet safety, West Pharmaceutical Services, Inc. (WST) carries a lower debt/equity ratio of 13% versus 51% for Johnson & Johnson — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), West Pharmaceutical Services, Inc.

(WST) is pulling ahead at 6. 3% versus 4. 3% for Johnson & Johnson (JNJ). On earnings-per-share growth, the picture is similar: West Pharmaceutical Services, Inc. grew EPS 1. 6% year-over-year, compared to -57. 8% for Johnson & Johnson. Over a 3-year CAGR, JNJ leads at 4. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

West Pharmaceutical Services, Inc.

(WST) is the more profitable company, earning 16. 1% net margin versus 15. 8% for Johnson & Johnson — meaning it keeps 16. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JNJ leads at 24. 9% versus 20. 1% for WST. At the gross margin level — before operating expenses — JNJ leads at 69. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, West Pharmaceutical Services, Inc. (WST) is the more undervalued stock at a PEG of 4. 38x versus Johnson & Johnson's 34. 49x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Johnson & Johnson (JNJ) trades at 19. 4x forward P/E versus 36. 3x for West Pharmaceutical Services, Inc. — 16. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for JNJ: 11. 0% to $249. 27.

All stocks in this comparison pay dividends.

Johnson & Johnson (JNJ) offers the highest yield at 2. 2%, versus 0. 3% for West Pharmaceutical Services, Inc. (WST).

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

06), 2. 2% yield, +136. 2% 10Y return). Both have compounded well over 10 years (JNJ: +136. 2%, WST: +353. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

JNJ pays a dividend while WST does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.